Celiprolol
 | |
|---|---|
| Systematic (IUPAC) name | |
| (RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Legal status | ? |
| Pharmacokinetic data | |
| Bioavailability | 30-70% |
| Half-life | 5 hours |
| Identifiers | |
| CAS number | 56980-93-9 |
| ATC code | C07AB08 |
| PubChem | CID 2663 |
| ChemSpider | 2563 |
| UNII | DRB57K47QC  |
| KEGG | D07660 |
| ChEMBL | CHEMBL27810 |
| Chemical data | |
| Formula | C20H33N3O4 |
| Mol. mass | 379.49 g/mol |
| SMILES
| |
Celiprolol (brand names Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm) is a medication in the class of beta blockers, used in the treatment of high blood pressure. It has a unique pharmacology: it is a selective β1 receptor antagonist, but a β2 receptor partial agonist. It is also a weak α2 receptor antagonist.
A recent clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial rupture in which the layers of the vessel separate prior to complete failure of the artery wall).[1]
References
- ↑ Ong K-T et al. (2010). "Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial". Lancet 376 (9751): 1476–1484. doi:10.1016/S0140-6736(10)60960-9. PMID 20825986.
External links
- Selectol Summary of Product Characteristics (from the IPHA Medicines Compendium)
- Celiprolol data sheet for New Zealand
| |||||||||||||||||||||||